|
Pelegrín P. Many ways to dilate the P2X7 receptor pore. Br J Pharmacol. 2011 Jul;163(5):908-11. doi: 10.1111/j.1476-5381.2011.01325.x. PubMed PMID: 21410461; PubMed Central PMCID: PMC3130938.
AÑO: 2011; IF: 4.409
|
21410461
|
Roger S, Pelegrin P. P2X7 receptor antagonism in the treatment of cancers. Expert Opin Investig Drugs. 2011 Jul;20(7):875-80. doi: 10.1517/13543784.2011.583918. Epub 2011 May 27. PubMed PMID: 21619470.
AÑO: 2011; IF: 5.274
|
|
Keating C, Pelegrin P, Martínez CM, Grundy D. P2X7 receptor-dependent intestinal afferent hypersensitivity in a mouse model of postinfectious irritable bowel syndrome. J Immunol. 2011 Aug 1;187(3):1467-74. doi: 10.4049/jimmunol.1100423. Epub 2011 Jun 22. PubMed PMID: 21697458.
AÑO: 2011; IF: 5.788
|
|
Roger S, Gillet L, Baroja-Mazo A, Surprenant A, Pelegrin P. C-terminal calmodulin-binding motif differentially controls human and rat P2X7 receptor current facilitation. J Biol Chem. 2010 Jun 4;285(23):17514-24. doi: 10.1074/jbc.M109.053082. Epub 2010 Apr 8. PubMed PMID: 20378545; PubMed Central PMCID: PMC2878516.
AÑO: 2010; IF: 5.328
|
|
Lopez-Castejon G, Theaker J, Pelegrin P, Clifton AD, Braddock M, Surprenant A. P2X(7) receptor-mediated release of cathepsins from macrophages is a cytokine-independent mechanism potentially involved in joint diseases. J Immunol. 2010 Aug 15;185(4):2611-9. doi: 10.4049/jimmunol.1000436. Epub 2010 Jul 16. PubMed PMID: 20639492.
AÑO: 2010; IF: 5.745
|